The Great Debate: Medicine or Surgery. What Is Best for the Patient with Type 2 Diabetes? by Lautz, David et al.
 
The Great Debate: Medicine or Surgery. What Is Best for the
Patient with Type 2 Diabetes?
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Lautz, David, Florencia Halperin, Ann Elizabeth Goebel-Fabbri,
and Allison Braunwald Goldfine. 2011. The great debate:
Medicine or surgery. What is best for the patient with type 2
diabetes? Diabetes Care 34(3): 763-770.
Published Version doi:10.2337/dc10-1859
Accessed February 19, 2015 9:56:37 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10021412
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAThe Great Debate: Medicine or Surgery
What is best for the patient with type 2 diabetes?
DAVID LAUTZ, MD
1,2
FLORENCIA HALPERIN, MD
1,3,4 ANN GOEBEL-FABBRI, PHD
3,5
ALLISON B. GOLDFINE, MD
1,3,4
I
n 1991, a National Institutes of Heath
expert consensus panel recommended
bariatric surgery to treat obesity for
informed and motivated patients with
BMI .40 kg/m
2, or between 35 and 40
kg/m
2 with high-risk comorbid conditions
including diabetes, in whom operative
risks are acceptable (1). In December
2010, these guidelines were reviewed by
the Gastroenterology and Urology Devi-
ces Panel of the Medical Devices Advisory
Committee of the Food and Drug Admin-
istration, with recommendation to lower
the criteria for use of the laparoscopic ad-
justable gastric band to BMI .30 kg/m
2
for patients with comorbidity. Surgical
treatments of obesity induce impressive
absolute weight loss of 30–40 kg (;60%
excess weight, ora 10–15 kg/m
2 reduction
in BMI) (2), which may be sustained over
10–15 years (3). Increasing medical and
public awareness of sustained weight loss,
increased ease of recovery, and lowered
complications with newer laparoscopic
surgical procedures and the ongoing in-
creased incidence of obesity have contrib-
uted to a 15-fold increase in bariatric
surgical procedures in the past decade,
with estimates of .200,000 procedures
having been performed in the United
States in 2007 (4).
Recent observational studies demon-
strate that bariatric surgical procedures
reduce the incidence of type 2 diabetes
and lead to substantial improvement or
“resolution” for many patients with pre-
existing disease. Type 2 diabetes has
“resolved” (deﬁn e di nt h es u r g i c a ll i t e r -
ature as maintenance of normal blood
glucose after discontinuation of all
diabetes-related medications, in most
studies with HbA1c ,7%) in ;77% of pa-
tients who undergo obesity surgery, and
resolved or improved in ;85%, with sus-
tained improvements in multiple meta-
bolic measures, such as fasting plasma
glucose and insulin, percent glycosylated
hemoglobin,anduseofantidiabeticmed-
ications (2,5–9). Patients with shorter
duration of disease seem to have more
complete or sustained disease resolution
(10). Furthermore, dyslipidemias and
hypertension markedly improve or re-
solvein70–95%and87–95% ofsurgically
treated patients, respectively. In one ob-
servational study, gastric bypass surgery
resulted in a 40% decreased relative risk
of death compared with matched control
patients, and diabetes-related deaths
were reduced by 92% (11). Health eco-
nomic evaluations suggest reductions in
use of medications and overall health
care costs for patients with type 2 diabe-
teswhohaveundergonebariatricsurgery
(8). Although some physicians consider
bariatric surgery draconian (12), these
data suggest important health beneﬁts
of surgical interventions in patients with
type 2 diabetes with BMI .35 kg/m
2 and
raise the question of whether surgical in-
terventions should be considered earlier
i nt h ec o u r s eo fd i s e a s eo rf o rl e s s e rm a g -
nitude of excess weight and speciﬁcally
for the treatment of diabetes as opposed
to treatment of obesity.
Mechanisms of weight loss after
bariatric surgery
The effectiveness of bariatric surgical pro-
cedures in improving type 2 diabetes was
originally ascribed to substantial dietary
changes and weight loss (13). More re-
cently, several lines of evidence suggest
that bariatric surgical procedures, espe-
cially the Roux-en-Y gastric bypass
(RYGB), have glycemic effects in part in-
dependent of weight loss. Such evidence
includes 1) animal data showing that di-
version of enteral ﬂow from the duode-
num, which occurs in RYGB, improves
type 2 diabetes even in nonobese animals
(14); 2) patients receiving RYGB experi-
ence greater early improvements in glyce-
mia compared with patients receiving
laparoscopic adjustable gastric band
(LAGB) on the same postoperative diet
(15); 3) in contrast with LABG, very early
improvements in insulin sensitivity and
b-cell function have been demonstrated
(15,16); 4) a small group of patients
have recently been identiﬁed who have
developed late-onset hyperinsulinemic
hypoglycemia after RYGB, usually mani-
festing after maximal weight loss results
have been realized (17,18), implicating a
potentialchronicstimulatoryeffectonthe
b-cell; and 5) altered nutrient delivery
throughthegastriccomparedwith gastric
bypass route alters glucose tolerance, in-
sulin dynamics, and other metabolic
measures (19,20).
Ongoing controversy exists as to the
mechanism(s) underlying metabolic im-
provements following bariatric surgical
proceduresintype2diabetes.Initialideas
focused on restrictive and malabsorptive
processes. However, increasingly recog-
nized are the enterohormonal changes and
neuronal events elicited by post-RYGB
anatomy. These involve communication
directly to the central nervous system to
regulate feeding behavior and energy
balance, and alterations in liver, adipose,
muscle, and pancreatic physiology to di-
rectly and indirectly alter glycemia, and
insulin secretion and action. Competing
theories have been popularized as to the
mechanisms of these effects. The proposed
“lower intestinal hypothesis” is based on
the documented substantial changes in
incretin and other entero-endocrine re-
sponses from more direct nutrient delivery
to the distal intestine (21,22). The impor-
tance of early nutrient delivery to the distal
small bowel is clearly supported by ileal
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REVIEWtransposition experiments, in which a seg-
ment of the ileum is moved proximally to
the duodenal-jejunal junction, leading to
reduced food intake and weight loss
withoutfatmalabsorptionandassociated
with increased glucagon-like peptide-1
(GLP-1), peptide YY, and preproglucagon
( 2 3 ) .A l t e r n a t i v e l y ,a n“upper intestinal
hypothesis” theorizes that diverting nu-
trientﬂowfromtheproximalsmallbowel
removes the stimulus for the production
of a “diabetogenic signal” (14,24), as best
demonstrated by Rubino and colleagues
(25) in a series of elegant surgical experi-
ments demonstrating glycemic improve-
mentwithduodenal-jejunalbypass(DJB)
compared with sham-operated or diet-
treatedGKnonobesediabeticrats.Glyce-
mic improvements were not sustained
when gastrojejunal nutrient transit was
restored. Glycemic improvement with-
out weight loss has also been seen in hu-
mans with DJB procedures. Perhaps the
RYGB is so effective in reducing weight
and hyperglycemia because it incorpo-
rates the multiple mechanisms discussed
above.
The study of enterohormonal changes
after different bariatric surgeries and how
these relate to metabolic change and sus-
tained weight loss is an emerging ﬁeld.
Among the best studied enterohormones
is ghrelin, which is synthesized in the
stomach. Concentrations increase before
mealsandstimulateappetite,participating
intheinitiationoffeeding.Speciﬁcdietary
lipids may serve as substrates for acyla-
tion of ghrelin, which modify its activity,
thereby providing a mechanism for com-
munication between nutrient availability
and metabolic status (26). With diet-
inducedweightlossghrelinconcentrations
increase, driving appetite and promoting
weight regain. In contrast, after RYGB
ghrelin levels decrease, contributing to
reducedfoodseekingactivityandpromot-
ingsustainedweightloss(27).Atthesame
time, peptides produced postprandially
from the L-cells of the ileum, including
GLP-1, peptide YY, and oxyntomodulin,
allincrease,likelybecauseofearlynutrient
delivery to the ileum and neuronal mech-
anisms (21,22). All of these peptides have
been associated with satiation, likely fur-
ther contributing to sustained weight loss.
These changes are not seen with LABG or
diet-induced weight loss. Some of these
enterohormonal changes, including in-
creased GLP-1, may promote pancreatic
islet regeneration or maintenance of mass
or function. Expression of pancreatic
duodenal homeobox-1, an early and
essential transcription factor in the b-cell
lineage, and bromodeoxyuridine (a syn-
thetic thymidine analog that gets incorpo-
rated into a cell’s DNA when the cell is
dividing) uptake into b-cells are both in-
creased after RYGB, supporting positive
islet effects (28). However, whether there
is increased islet mass or function after
gastric bypass remains highly controver-
sial (29). Very recent feeding tube case re-
ports suggest that the route of nutrient
delivery seems to be a primary and poten-
tiallyreversibleeventinelicitingthisentero-
endocrine and b-cell response (19,20).
Type 2 diabetes: a surgical disease?
The ongoing diabetes epidemic, the im-
pressive effectiveness of bariatric surgical
procedures in treating type 2 diabetic
patients, and the lines of evidence sug-
gesting weight-independent effects of
theseproceduresonglycemia,considered
together, have resulted in substantial
enthusiasm in the surgical community
for lowering the minimal BMI criteria for
bariatric surgical candidates with type 2
diabetes. This would in effect be the ﬁrst
stepinmakingtype2diabetesasurgically
treated disease, and this proposal has
been the subject of two recent interna-
tional consensus conferences (30).
However, treating type 2 diabetes
with bariatric surgery remains highly
controversial in the endocrinology com-
munity (12). First, it must be emphasized
that the evidence suggesting that bariatric
surgical procedures may have direct ef-
fects on glycemia independent of weight
loss include very few randomized con-
trolled trials, and most surgical outcomes
are from uncontrolled case series with
considerable missing data (9). In one
meta-analysis, a large number of studies
did not report enrolling consecutive pa-
tients, and less than half reported the
number of patients available for follow-
up (7). To date, the only prospective ran-
d o m i z e dc o n t r o l l e dt r i a lo nt h es u b j e c t
evaluated the effects of the LAGB, a pro-
cedure generally thought to not have
weight-independent effects on glycemia
(6). Thus, the substantial lack of level 1
evidence precludes achievingaconsensus
across specialties.
Second, concurrent to the advances
in the surgical treatment of type 2 di-
abetes, there have been signiﬁcant ad-
vances in the medical management of the
disease. Since 1995 there have been mul-
tiple new drugs approved by the Food
and Drug Administration for the treat-
ment of hyperglycemia in patients with
type 2 diabetes, including the biguanide
metformin, a-glucosidase inhibitors, thia-
zolidinediones, glinides, GLP-1 analogs,
amylin analogs, dipeptidyl peptidase-IV
inhibitors (31), a bile acid sequestrant
(32),andmostrecentlyadopaminerecep-
tor agonist (33). In addition, multiple in-
sulin analogs are now available (34) with
improved kinetics and safer dosing pro-
ﬁles permitting more individualized and
safer regimens compared with prior prep-
arations. Novel pharmacologic agents to
promote weight loss are also under devel-
opment (35,36). Together these agents
hold great promise for generating im-
proved health outcomes for type 2 dia-
betic patients, and with them more
patients are achieving metabolic targets.
However, long-term safety remains in-
completely understood, and some agents
may impart undesirable risks for adverse
outcomes,suchasthepotentialforcardio-
vascular risk with rosiglitazone (37) or
pancreatitis with exenatide (38). Optimal
treatment strategies and glycemic goals
for patients with type 2 diabetes remain
incompletely understood, and very tight
glycemic control may not reduce cardio-
vascular event rates, and may even lead to
increased mortality (39). Thus, just as
with surgical therapy of the disease, fur-
ther study is needed on the effects of cur-
rent combination and long-term medical
therapeutic regimens on type 2 diabetes.
Understanding the long-term safety and
efﬁcacy of pharmacologic weight loss
agents will likewise be important to con-
sider (36,40).
A growing number of investigators
have initiated efforts to provide level 1
data relevant to determining optimal
treatment regimens for type 2 diabetes
given the current equipoise for the clini-
cian to recommend surgical or medical
interventions. There are currently 11
studies registered on Clinicaltrials.gov
comparing various bariatric and medical
interventions (Table 1) (clinicaltrials.gov,
accessed 20 September 2010). The Na-
tional Institute of Diabetes and Digestive
andKidney Diseaseshas funded four pro-
spective pilot and feasibility trials in the
past year, possibly in consideration of
a larger nationally based outcome trial to
follow. With the societal imperative to
provideoptimalcareforthegrowingpop-
ulation of patients with diabetes, the in-
tense scientiﬁc focus on medical and
surgical option effectiveness, and such a
rapid expansion of clinical trials on the
matter, a number of relevant issues are
brought to bear by those designing,
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Lautz and Associatesconducting, reviewing, and ultimately in-
terpreting such trials.
Bariatric surgical procedures
When either recommending surgery to a
patient or designing a trial, it is important
to consider which surgical procedure to
select. There are several options.
The LAGB is a commonly chosen
bariatric surgical procedure in the U.S.
and has a highly acceptable safety risk
proﬁle, making it attractive for less obese
patients as an alternative to medical ther-
apy. Thirty-day mortality was zero in
1,198 patients who underwent LAGB
placement (41). Most surgical studies re-
port results as mean percent excess body
weight loss calculated as the percent of
body weight above Metropolitan Life
table “ideal” (42), or alternatively BMI of
25 kg/m
2. The mean percent excess body
weightlossafterLAGBinpublishedseries
i s4 6 %,an dth eme anr es ol ut io ni ndi a be-
tes is 56% (2), both substantially lower
than after RYGB (2). Studies that directly
comparetheRYGBandLAGBalsosuggest
substantially greater weight loss and res-
olution of comorbidities after RYGB (43).
There are no studies to date suggesting
that the LAGB has a speciﬁc effect on
type 2 diabetes beyond that of inducing
caloric restriction and subsequent weight
loss. However, as noted above, the only
level 1 data comparing medical with sur-
gical interventions speciﬁcally for the
treatment of type 2 diabetes evaluates
LAGB as the surgical procedure. Dixon
et al. (6) randomized patients recently di-
agnosed with type 2 diabetes (diagnosis
#2y e a r s )w i t hB M I3 0 –40 kg/m
2 (inclu-
sive of some patients whose weight was
below current bariatric surgical criteria)
to LAGB or an intensive lifestyle modiﬁ-
cation with medical management, and
demonstrated surgically treated patients
were more likely to achieve diabetes “re-
mission” (deﬁned as fasting glucose level
,126 mg/dL and glycated hemoglobin
,6.2% without glycemic therapy) (73
vs. 13%, P , 0.001), with a 5.5 relative
risk for remission in the surgically treated
group. Notably, the magnitude of weight
loss achieved in this study substantially
exceedsthattypicallyrealizedinU.S.clin-
ical practice (2). Whether with similar
techniques and management algorithms
the same level of results can be attained
in a less obese population with type 2 di-
abetes in the U.S. remains unknown. The
LAGB seems to have the lowest complica-
tion and adverse outcome rate among
commonly performed bariatric surgical
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The great debate: medicine or surgeryprocedures (41,43). More frequent com-
plicationsofLABGincludegastricerosion
or perforation, band slippage or migra-
tion, esophageal dilation, port problems,
incisional hernias, and acute respiratory
distress and pulmonary embolism (44).
Therefore, despite the lack of evidence
for a speciﬁc effect, with a low-risk proﬁle
and impressive results from Dixon and col-
leagues’ prospective randomized series, the
LAGB certainly is an attractive therapeutic
option. Although, it is important to note
that the band will require adjustments,
potentially over the patient’s lifetime.
The RYGB is also a commonly per-
formed procedure,and despitethelackof
randomized clinical trials comparing
RYGB with medical intervention, much
of the enthusiasm for expansion of BMI
criteriaforbariatricsurgicalproceduresin
type2diabeticpatientshasbeenfueledby
RYGB outcomes demonstrated in multi-
ple large observational studies that show
improvement or resolution of diabetes in
80% of patients who undergo this pro-
cedure (2). Despite early concerns over
safety proﬁles, the laparoscopic RYGB
h a sb e e nj u d g e dt ob ea ne x t r e m e l ys a f e
procedure. Estimates of early operative
mortality, deﬁned as mortality at 30
days or less, vary, but in general are at
0.1–0.33% (4,45), and this has been sup-
ported by a recent large prospective
multi-institutional trial involving 2,975
laparoscopic RYGB procedures, showing
a 0.2% 30-day postoperative mortality
rate (41). Higher rates exist for open
RYGB, with elderly patients and with
less experienced surgeons (46). Compli-
cations of RYGB can occur in up to 10%
of patients. Other risks include reopera-
tion during the same admission in 6–9%;
technical complications, including ob-
struction, anastomotic, hemorrhagic,
wound, and splenic injury in 1–2%; and
systemic complications in 3–7%, which
most commonly involve the pulmonary
system (4). In addition, the rate of overall
hospital admissions in the year after
RYGB surgery may be increased twofold,
with most admissions for gastrointestinal
or surgical-related complications (45).
Many of these risks are continuing to di-
minish over time with the increasing prev-
alence of laparoscopic techniques and
growingclinicalexperienceandprevalence
of bariatric surgical centers of excellence
(47).Asdiscussedabove,thereismounting
evidencethatimprovementorresolutionof
diabetes after RYGB includes mechanisms
beyond weight loss alone. Although there
are no randomized controlled trials of
RYGB compared with nonsurgical inter-
ventions, the proven effectiveness and
safetyproﬁlecautiouslysupporttheprefer-
ential use of this procedure speciﬁcally for
type 2 diabetes treatment.
It is important to note there are
variations in the speciﬁcs u r g i c a lt e c h -
niques of the RYGB procedure. These
include concomitant vagotomy or vagal-
sparing maneuvers (48) at the time of
RYGB, as well as variable limb length.
With regard to limb lengths, a “standard
limb length” RYGB procedure includes a
30–50 cm pancreaticobiliary limb and a
75–100 cm Roux limb (49). Lengthening
the pancreaticobiliary and Roux limbs to
150cmsigniﬁcantlyincreasesmalabsorp-
tion and potential complications (49).
Thus, outcomes after RYGB need to be
interpreted with differences in surgical
technique taken into account.
Several other bariatric surgical proce-
dures options exist. The biliopancreatic
diversion and duodenal switch are ex-
tremely effective at reducing weight and
hyperglycemia but have documented
higher perioperative mortality rates and
induce substantial malabsorption (50),
which are less appropriatefor a population
with lower BMI. The laparoscopic sleeve
gastrectomy (LSG) is a newer procedure
that is rapidly gaining favor nationally. To
date, most studies using this procedure on
less obese type 2 diabetic patients have
been in conjunction with ileal interposi-
tion,whichsigniﬁcantlyincreasesthecom-
plexityoftheoperationbutmaycontribute
positively to effects on the incretin axis
(51). Rapid adoption of the LSG technique
in many centers throughout the U.S. is
likely to provide relevant data in the near
future,andassuch,goingforward,theLSG
may be an important option to be consid-
ered in clinical trials.
Novel procedures that have been de-
signed speciﬁcally to address type 2 di-
abetes include the ileal interposition and
theDJB,mentionedabove(25).However,
there are insufﬁcient human clinical data
to justify using them broadly at this time.
The DJB involves division and anastomo-
sis of the duodenum and thus also likely
carries a higher risk for perioperative
morbidity and mortality (52).
Finally, minimally invasive devices,
such as the intraluminal duodenal sleeve,
have been demonstrated in preclinical
models to effectively reduce weight with-
out malabsorption and improve oral and
intraperitoneal glucose tolerance (53).
Earlyclinical trialssuggest similar devices
may promote weight loss and glycemic
improvements in patients with type 2 di-
abetes (54).
Differences in surgical approaches
must be considered when weighing the
mostappropriateinterventionatthistime
either for individual therapy or for study
in a prospective trial evaluating surgical
approachesdirectedattype2diabetes.To
change practice guidelines touse bariatric
procedures in lesser degrees of obesity
and earlier in the course of diabetes,
speciﬁcallyfordiabetestreatment,studies
must be conducted to compare surgical
with medical management. From a trial
perspective, consideration as to the type
of surgical procedure(s) to include must
also hinge on currently accepted insur-
ance practices. It is unlikely larger trials
would have sufﬁcient funding to bear the
entire clinical cost of the surgical proce-
dures, and thus would have to rely on
someoftheclinicalcostsbeingcoveredby
multiple funding agencies, including in-
surers, to successfully complete a large
adequately powered outcome study.
Advanced nonsurgical management
of weight and type 2 diabetes
Patientswithtype2diabeteshavedifﬁculty
losing weight and maintaining weight loss.
Pharmacologic management of diabetes
remains controversial, both from the per-
spective of the best medications to pre-
scribe and the optimal glycemic targets.
Many new classesofdrugshavebeenFood
and Drug Administration approved for the
managementoftype2diabetesonthebasis
of glucose-lowering properties. Although
many diabetes medications are associated
with weight gain, including insulin, sulfo-
nylureas, and thiazolidinediones, more re-
cently approved medications are weight
neutral (dipeptidyl peptidase-4 inhibitors
or bile acid sequestrants) or promote
weight loss (GLP-1 analogs and amylin
analogs). However, the long-term risks of
neweragents remainless certain, and these
agents are considered tier 2 in consensus
algorithms (55).
Nonsurgical behavioral approaches to
weight loss have been studied for decades.
Mostevidencesupportstheeffectivenessof
combining moderate dietary changes and
increased physical activity—an approach
referred to as a “lifestyle intervention”—
for achieving modest weight loss and
maintaining weight improvements over
time. Long-term evidence is now available
supporting the power of lifestyle inter-
ventions to prevent the onset of type 2
diabetes in high-risk populations (56);
however, patients already diagnosed with
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and maintaining weight loss than patients
without diabetes (57). The LookAHEAD
trial (Action for Health in Diabetes) is a
large-scale, multicenter clinical trial inves-
tigatingtheimpactoflifestyleintervention
on cardiac outcomes in more than 5,000
patients with type 2 diabetes. Four-year
follow-updatafromLookAHEADsupport
the successful impact of lifestyle interven-
tions in achieving weight loss and im-
proved glycemic control in type 2 diabetic
patients (58). Participants in the lifestyle
arminitiallylostanaverageof8.6%oftheir
initial weight and experienced a mean de-
crease in glycohemoglobin from 7.3 to
6.6% during their ﬁrst year of Look-
AHEAD. After 4 years, 6.2% weight reduc-
tion was sustained in the lifestyle group
compared with only 0.9% reduction in
the control group; glycohemoglobin was
reduced 0.4% in the lifestyle group com-
pared with 0.09% in the control group.
Lifestyleparticipantsshowedsustainedim-
provements in blood pressure, cholesterol,
and physical ﬁtness. Current results of
LookAHEAD (58) and other studies al-
ready support the use of lifestyle interven-
tions to improve overall health and
wellness of patients with diabetes.
The best weight loss outcomes result
from interventions that include multidisci-
plinaryteamswithbehavioralmodiﬁcation
components, frequent contact individually
or in group programs, and administration
of long-term support. Substantial funding
isneededtocarryouttheseinterventionsin
research or clinical care settings. Private
insurance reimbursement for such pro-
grams may become more widely available
now that Medicare recognizes obesity as a
chronic disease. Thus, insurance-billable,
cost-effective multidisciplinary approaches
are emerging in clinical practice that target
both diabetes and weight management.
One such example is the Why WAIT
(Weight Achievement and Intensive Treat-
ment) program, which consists of 12
weekly group sessions led by nutrition,
exercise physiology, mental health, and
diabetes care providers, followed by
monthlysupportaimedatlong-termmain-
tenance ofweight loss and diabetes control
(59).Unfortunately,onanationallevel,few
patients participate in these types of inten-
sive medical management programs.
Bariatric surgery or medical
management? The informed decision
Prospective randomized studies to eval-
uate the important question of whether
medical or surgical management is opti-
mal for treatment of type 2 diabetes in
moderately obese patients are now war-
ranted. Trials should aim to identify char-
acteristics of patients who do well and
have improved outcomes compared with
those who do not so that therapeutic
recommendations can be individualized
when possible. Trials must be designed to
optimize the quality and applicability of
the information generated, and there are
multiple important methodological is-
sues. Foremost, is the type of surgical
procedures to be considered and whether
one or more procedures would be com-
pared with standard care or an intensive
diabetes and weight management pro-
gram? If multiple procedures were to be
considered, patients may be unwilling
to relegate the choice of procedure to a
randomized process, and this could rep-
resent a signiﬁcant impediment to subject
accrual and study feasibility or generaliza-
tionofﬁndings.Patientpreferencetowarda
speciﬁcp r o c e d u r ei ss t r o n g ;i nas u r v e yo f
2,046 patients in our surgical clinic, 46%
preferred RYGB, 42% preferred LAGB,
and only 12% had no preference (D.L.,
unpublished data). Patient and provider
biases may differ for patients selected
from surgical clinics compared with pri-
mary care or endocrine practices. To
informthedecisionontherelativebeneﬁt
ofsurgerytomedicalcare,itisessentialto
optimizethemedicaldiabetesandweight
management for appropriate compari-
son, rather then compare with standard
of care, where many patients may not
meet combined glycemic, blood pressure,
and lipid goals.
Many deem it most important to
study patients with type 2 diabetes who
are not currently approved for bariatric
procedures,that is, those with aBMI,35
kg/m
2. In further consideration of patient
selection, excluding patients with very
poor glycemic control may be prudent
to avoid excess perioperative risks. Con-
versely,including onlypatients withpoor
glycemic control or requiring patients to
have inadequately achieved weight loss
or glycemic improvement after a period
of medical management (typically a
6-month period is currently necessary
for many health insurance providers)
could bias study results against the med-
ical intervention, because the study
would then speciﬁcally be selecting those
who have been unable to achieve optimal
control with nonsurgical treatments. In
addition, requiring patients to have
higher glycohemoglobin concentrations
may select against those with more recent
onset of disease who may beneﬁtm o s tb y
long-standing disease resolution (10). In
consideration of current medical treat-
ment for diabetes, some data suggest pa-
tients using insulin may not achieve the
samedegreeofresolutionofdiabetesafter
surgical procedures (60), possibly be-
cause insulin use is more prevalent in
patients with more long-standing or ad-
vanced disease. However, insulin is now
frequently used as a second or early phar-
macologic intervention because of the
clear success in improving glycemia
(55), making itdifﬁcult to justifyexclusion
of insulin-treated patients. Stratiﬁcation
for some of these important covariates
may be necessary to apply future study
ﬁndings to speciﬁc patient populations.
Finally, the outcome measures rele-
vant to clinical trials designed to compare
the efﬁcacy of surgical and medical man-
agement of type 2 diabetes will undoubt-
edly include achievement of glycemic
targets, such as fasting and postprandial
blood glucose levels, glycohemoglobin
concentrations, continued use of diabetes
medications, weight loss, or a combina-
tion of these variables. Although deﬁning
improvement in glycemic control may be
straightforward, deﬁning “cure” of the
disease has proven controversial; “remis-
sion” is likely a more accurate term. In
2009, a consensus group deﬁned remis-
sion of diabetes as achievement of glyce-
m i ab e l o wt h ed i a b e t i cr a n g ei nt h e
absence of active pharmacologic therapy
orongoingprocedures(e.g.,repeatedgas-
tric band adjustments or replacements of
endoluminal devices). Partial remission
was deﬁned as hyperglycemia below the
diabetic range (HbA1c ,6.5%, fasting glu-
cose 100–125 mg/dL [5.6–6.9 mmol/L])
for at least 1 year; complete remission
wasdeﬁnedasareturntonormoglycemia
(normal HbA1c and fastingglucose,100
mg/dL [5.6 mmol/L]) for at least 1 year;
and prolonged remission was deﬁned as
completeremissionforatleast5years(61).
Although improved glycemia is rec-
ognized to be an important outcome in
patients with diabetes, diabetes is charac-
terized by high rates of microvascular and
macrovascular complications; thus, well-
designed long-term studies will be
needed to determine the effect of each
management strategy on the risk of such
complications. Following surrogate end
points, such as albuminuria, lipid pro-
ﬁles, hypertension, markers of inﬂamma-
tion, and other cardiovascular risk
factors, in studies of shorter duration
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comeavailable.Longer-termstudiesshould
also help clarify the postoperative health
risks that may arise over time, such as
changes in micronutrients, bone mineral
density and fracture risk, the risk of
postoperative hypoglycemia, and others.
Conclusions
Emerging data suggest that bariatric sur-
gery results in substantial improvements
in glycemia, blood pressure, and choles-
terol; weight loss is durable; survival may
be improved; and surgical risks are low.
Novel surgical approaches are under de-
velopment. At the same time, there have
been substantial medical advances, and
multiple pharmacologic agents are now
available to treat diabetes and manage
cardiovascular risk; pharmacologic weight
loss agents and multipronged lifestyle
strategies with multidisciplinary care are
showing promise. Understanding the rel-
ative risks and beneﬁts of different treat-
mentapproachesforindividualswithtype
2 diabetes, as well as the health care and
other costs of such treatments, on a soci-
etal level will be of utmost importance in
the coming years. Lessons from the study
of the neurohormonal changes after bar-
iatricsurgerymayinformnotonlythebest
surgical procedure but also lead to de-
velopment of novel medical therapies,
gastrointestinal interventions, or combi-
nation approaches to offer optimal man-
agementforthepreventionortreatmentof
type 2 diabetes.
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